Avidity Biosciences, Inc. Common Stock

RNA

...

RNA: Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.

Show RNA Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of RNA by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by RNA's directors and management

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

U.S. Patents

New patents grants

Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Aug. 01, 2023
Patent Title: Compositions and methods of treating muscle dystrophy Jul. 25, 2023
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 21, 2023
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Feb. 14, 2023
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 14, 2023
Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Jan. 17, 2023
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 17, 2023
Patent Title: Compositions and methods of treating facioscapulohumeral muscular dystrophy Dec. 13, 2022
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Nov. 15, 2022
Patent Title: Compositions and methods of treating muscle dystrophy Sep. 20, 2022
Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Aug. 02, 2022
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Jun. 21, 2022
Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Apr. 26, 2022
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 22, 2022
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Feb. 15, 2022
Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping Nov. 23, 2021
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Sep. 07, 2021
Patent Title: Anti-transferrin receptor antibodies and uses thereof Jun. 08, 2021
Patent Title: Nucleic acid-polypeptide compositions and methods of inducing exon skipping May. 04, 2021
Patent Title: Anti-transferrin receptor antibodies and uses thereof Feb. 09, 2021
Patent Title: Compositions and methods of treating muscle atrophy and myotonic dystrophy Jan. 05, 2021
Patent Title: Egfr nucleic acids and uses thereof Dec. 29, 2020
Patent Title: Kras nucleic acids and uses thereof Dec. 08, 2020
Patent Title: Beta-catenin nucleic acids and uses thereof Nov. 24, 2020
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Oct. 13, 2020
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Sep. 29, 2020
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Feb. 04, 2020
Patent Title: Nucleic acid-polypeptide compositions and uses thereof Nov. 26, 2019

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on RNA's company Twitter account

WallStreetBets

Number of mentions of RNA in WallStreetBets Daily Discussion

RNA News

Recent insights relating to RNA

CNBC Recommendations

Recent picks made for RNA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RNA

Corporate Flights

Flights by private jets registered to RNA